The cost of radiotherapy for 5-year local control and overall survival benefit

V. Batumalai1-3, K. Wong1-3, J. Shafiq2,3, T. Hanna2, G. Gabriel2,3, J. Heberle4, I. Koprivic4, N. Kaadan1, O. King1, T. Tran1, L. Cassapi1, D. Forstner1, G.P. Delaney1-3, M. Barton1-3

1Department of Radiation Oncology, South Western Sydney Local Health District; 2Collaboration for Cancer Outcomes Research and Evaluation, Ingham Institute for Applied Medical Research; 3South Western Clinical School, University of New South Wales, Australia; 4Activity Based Management, New South Wales Health, Australia

Introduction
Identifying the optimal allocation of resources to improve health is a major challenge to policy makers. The rapid uptake of new treatment strategies over the last decade in an under-resourced global environment highlights the need to develop a better understanding of costs and benefits of radiotherapy (RT).

Aim
To estimate the costs of 5-year local control and overall survival benefits of radiotherapy in Australia.

Methods

Estimating benefit
Local control (LC) and overall survival (OS) benefits of RT at 5-years were identified through systematic literature review

Optimum fractions
The optimal number of fractions per treatment course was estimated for 26 tumour sites

Estimating cost
Activity based costing was used to allocate cost to all RT activities extracted from the local RT information system (July 2016 to June 2017)

Cost per fraction
Cost per activity (fraction) was determined by dividing the average total cost per patient by the average number of activities

Cost per benefit
Cost per LC=(No. of fractions/LC) X cost per fraction
Cost per OS=(No. of fractions/OS) X cost per fraction

Results

• The average cost per fraction for all cancers was AU$276.
• The estimated cost benefit of RT was AU$23,585 per 5-year local control and AU$86,480 per 5-year overall survival for all cancers.

Implications

• The cost of AU$86,480 would translate to AU$17,296 for 1-year overall survival gain. Therefore, the cost of radiotherapy is inexpensive if delivered optimally.
• Policy implications from this study include knowledge about cost to deliver radiotherapy to allow for valuation of the expected benefit at a population level.

Acknowledgement
This study was supported by Cancer Institute NSW.

Contact
Vikneswary.Batumalai@health.nsw.gov.au
Ingham Institute